BAROSI, GIOVANNI
 Distribuzione geografica
Continente #
NA - Nord America 355
EU - Europa 340
AS - Asia 198
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 897
Nazione #
US - Stati Uniti d'America 349
CN - Cina 191
IE - Irlanda 153
IT - Italia 55
FI - Finlandia 41
DE - Germania 40
SE - Svezia 21
GB - Regno Unito 15
UA - Ucraina 8
CA - Canada 5
BE - Belgio 4
IN - India 3
IR - Iran 3
MU - Mauritius 2
PL - Polonia 2
BR - Brasile 1
ES - Italia 1
EU - Europa 1
NP - Nepal 1
PA - Panama 1
Totale 897
Città #
Dublin 153
Chandler 120
Nanjing 46
Beijing 39
Ashburn 31
Jacksonville 27
Helsinki 24
Pavia 21
Nanchang 19
Lawrence 16
Medford 16
New York 16
Princeton 16
Wilmington 14
Hangzhou 13
Changsha 12
Hebei 12
Shenyang 12
Tianjin 12
Shanghai 10
Jiaxing 8
Gallarate 6
Toronto 5
Brussels 4
Milan 4
Augusta 3
Boardman 3
Hanover 3
Jinan 3
Los Angeles 3
Rome 3
Woodbridge 3
Orange 2
Piscataway 2
Polska 2
Pune 2
Verrua Po 2
Washington 2
Americana 1
Ann Arbor 1
Aosta 1
Ardabil 1
Casorate Sempione 1
Esslingen am Neckar 1
Fairfield 1
Falkenstein 1
Fuzhou 1
Kathmandu 1
Leawood 1
Modena 1
Monza 1
Norwalk 1
Padova 1
Redmond 1
San Francisco 1
Seattle 1
Segrate 1
Taizhou 1
Turin 1
Würzburg 1
Zanjan 1
Zhengzhou 1
Totale 713
Nome #
Altered fibronectin expression and deposition by myeloproliferative neoplasm-derived mesenchymal stromal cells 77
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 64
Thrombopoietin/TGF-β1 Loop Regulates Megakaryocyte Extracellular Matrix Component Synthesis 63
Thrombopoietin/TGF-β1 loop regulates megakaryocyte extracellular matrix component synthesis 61
The spleen of patients with myelofibrosis harbors defective mesenchymal stromal cells 61
Phenotypical, Functional and Genetic Characterization of Mesenchymal Stem Cells Derived from the Spleen of Patients with Myelofibrosis. 59
JAK2 exon 14 Skipping in Patients with Primary Myelofibrosis (PMF). 57
Splenic marginal zone cell lymphoma: report of an indolent variant without massive splenomegaly presumably representing an early phase of the disease. 55
EDA fibronectin–TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis 52
SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma 51
Primary Prophylaxis of Invasive Fungal Diseases in Allogeneic Stem Cell Transplantation: Revised Recommendations from a Consensus Process by Gruppo Italiano Trapianto Midollo Osseo (GITMO) 50
Deciding when to intervene: a Markov decision process approach 49
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). 48
Dysregulation of VEGF-induced proangiogenic Ca(2+) oscillations in primary myelofibrosis-derived endothelial colony-forming cells 47
Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity 47
Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies 42
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms 33
Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression 19
HEMATOPOIETIC PROGENITOR CELLS EXPRESSING VE-CADHERIN ARE DETECTABLE IN THE SPLEEN OF PATIENTS WITH MYELOFIBROSIS AND ARE IN CLOSE CONTACT WITH MICROVESSELS 1
Totale 936
Categoria #
all - tutte 3.471
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.471


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191 0 0 0 0 0 0 0 0 0 0 1 0
2019/2020203 60 77 0 2 0 2 13 1 7 21 18 2
2020/202160 5 1 0 11 0 4 0 12 21 5 1 0
2021/2022104 0 0 3 19 1 1 0 5 3 14 13 45
2022/2023337 34 35 3 26 29 25 2 17 153 2 7 4
2023/2024140 19 29 4 4 10 52 0 13 1 4 4 0
Totale 936